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SUMMARY
BACKGROUND—Evidence of substantial, quantifiable and preventable burdens of mortality 
hazard even after anti-tuberculosis treatment and cure would be a compelling, concrete, and useful 
measure of the value of prevention.
METHODS—We compared years of potential life lost between a cohort of 3 933 cured 
tuberculosis (TB) patients and 9 166 persons with latent tuberculous infection. We constructed a 
regression model to predict the expected years of potential life lost in each cohort and for 
demographic subgroups.
RESULTS—Among decedents, a history of fully treated TB is associated with a predicted 
average 3.6 more years of potential life loss than a comparable population without active TB. 
Greater longevity losses were predicted among those identified as White and Hispanic than among 
Black and Asian counterparts.
CONCLUSION—We found significant differences in predicted longevity of treated TB survivors 
relative to a similar group without active TB. These excess losses are substantial: a total of 14 158 
life-years or the equivalent of more than 188 75-year lifespans. These findings illustrate an 
important opportunity cost associated with each preventable TB case — an average of 3.6 
potential years of life. We conclude that substantial preventable mortality burdens remain despite 
adequate anti-tuberculosis treatment, a compelling rationale for more widespread and systematic 
use of prevention.
RESUME
Les preuves d’un risque accru de mortalité substantiel, quantifiable et évitable même après un 
traitement anti-tuberculeux et une guérison serait un argument fort, concret et utile en faveur de la 
prévention.
Nous avons comparé les années de vie perdues potentielles entre une cohorte de 3933 patients 
tuberculeux guéris et une autre de 9166 personnes ayant une infection tuberculeuse latente. Nous 
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avons construit un modèle de régression afin de prédire les années potentielles de vie perdues dans 
chaque cohorte et dans les différents sous-groupes démographiques.
Parmi les patients décédés, une histoire de tuberculose (TB) complètement traitée est associée à 
une moyenne prévue de 3,6 années potentielles de vie perdues par rapport à une population 
similaire sans TB active. De plus grandes pertes de longévité ont été prédites chez les personnes de 
race blanche et hispanique par rapport à leurs homologues noirs ou asiatiques.
Nous avons trouvé des différences significatives dans les prédictions de longévité de patients ayant 
survécu à une TB traitée par comparaison à un groupe similaire sans TB active. Ces pertes en 
excès sont substantielles : un total de 14 158 années de vie ou l’ équivalent de plus de 188 durées 
de vie de 75 ans. Ces constatations illustrent les coûts d’opportunité élevés associés à chaque cas 
de TB évitable — une moyenne de 3,6 années de vie potentielles. Nous concluons qu’un fardeau 
substantiel de mortalité évitable persiste en dépit du traitement approprié de la TB, ce qui 
constitue un argument irréfutable en faveur d’une utilisation plus vaste et systématique de la 
prévention.
RESUMEN
Las pruebas de la existencia de cargas considerables, cuantificables y prevenibles de un riesgo de 
mortalidad, incluso después del tratamiento, y la curación de la tuberculosis (TB) podrían 
representar medidas convincentes, concretas y útiles de la importancia de la prevención.
Se compararon los años de vida potencial perdidos de una cohorte de 3933 pacientes curados de 
TB y 9166 personas con infección tuberculosa latente. Se construyó un modelo de regresión 
destinado a predecir los años de vida potencial perdidos previstos en cada cohorte y en los 
subgrupos demográficos.
En los difuntos, un antecedente de TB con tratamiento completo se asoció con un promedio de 3,6 
años de vida potencial perdidos, con respecto a una población comparable sin TB activa. Se 
pronosticaron mayores pérdidas de longevidad en las personas de etnia blanca o hispánica en 
comparación con sus homólogos de etnia negra o asiática.
Se observaron diferencias significativas en la longevidad prevista de los sobrevivientes del 
tratamiento antituberculoso en comparación con un grupo análogo de personas sin TB activa. 
Estos excesos de pérdidas son considerables, un total de 14 158 años de vida o el equivalente de 
más de 188 vidas de 75 años. Los resultados del estudio ponen de manifiesto un importante coste 
de oportunidad asociado con cada caso de TB prevenible, en promedio de 3,6 años de vida 
potencial. Se concluye que pese al tratamiento adecuado de la TB, persisten importantes cargas 
prevenibles de mortalidad, que constituyen un argumento convincente en favor de la aplicación de 
una prevención más generalizada y sistemática.
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Tuberculosis (TB) is often considered a curable disease without lasting post-cure sequelae,1 
but an assumption that cure reliably restores patients to their baseline health may be 
incorrect. While cavitary lesions typically disappear on computerized tomography (CT) 
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scans following cure,2,3 there is evidence to suggest that poor health may linger long after 
treatment is completed and the patient is discharged from care.4–8 Such health deficits may 
be associated with a shortened lifespan.
TB is preventable. Well-established epidemiologic and clinical protocols exist to diagnose 
latent tuberculous infection (LTBI), evaluate risk for activation to TB disease, and reduce 
that risk through a course of antibiotics where indicated.9,10 As the limitations of cure as a 
fully adequate harm reduction strategy become better understood, TB control and 
elimination paradigms have begun to evolve. Clinicians and public health authorities are 
rethinking treatment and other decisions predicated on the assumption that cure and 
prevention produce equivalent health outcomes, as well as the notion that active TB is a 
discrete episode in a patient’s lifetime that ends with the completion of standard treatment.11 
For more than a decade, national medical organizations and the Centers for Disease Control 
and Prevention (CDC, Atlanta, GA, USA) have recommended targeted testing and treatment 
of persons at high risk of LTBI as a priority for controlling TB in the United States.9,12 
However, these recommendations have not been widely implemented,13,14 partly because of 
poor acceptance by health professionals,15 but also due to limited public health resources.16
Effective and efficient advocacy or allocation of system resources requires an evidence-
based comparison of outcomes to weigh the potential costs and benefits of various strategic 
choices or investments. Work has been done to identify TB-related morbidity and mortality 
taking place in the period between infection and death or cure,17 and the pulmonary 
impairment as well as relative mortality risks faced by former TB patients have been 
described.8 Nevertheless, the residual burdens of morbidity and mortality risks that remain 
after cure have not been quantified, and the marginal health losses associated with the failure 
to interdict a potentially preventable TB case, and the potential gains available from 
prevention, remain unknown. We sought to fill this knowledge gap by estimating the 
absolute burden of TB-associated mortality within a defined cohort of persons known to 
have completed anti-tuberculosis treatment. Our estimates will increase the understanding of 
the unmeasured health consequences of active TB and provide insight into the long-term 
benefits of TB prevention.
METHODS
The Tuberculosis Epidemiologic Studies Consortium (TBESC) is a partnership between the 
CDC’s Division of Tuberculosis Elimination and academic and public health collaborators at 
20 US sites.18 We used records from three of the TBESC sites, Texas, Massachusetts, and 
Washington’s Seattle/King County, to create a database for two groups: persons who had 
completed treatment for TB disease at least 6 years previously and a comparison population 
of persons with diagnosed LTBI.19,20
Criteria for inclusion in the database included 1) age ≥18 years at treatment initiation (for 
TB) or diagnosis (for LTBI); 2) sufficiently comparable demographic, clinical, and other 
data to allow adjusted analyses; and 3) sufficient identifiers to determine vital status in the 
National Death Index (NDI). In addition, TB survivors had to have 1) TB diagnosed, 
reported, and treatment completed between 1 January 1993 and 31 December 2002; 2) 
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treatment completed within 3 years of initiation; and 3) alive at treatment completion. 
Additional criteria for inclusion in the comparison group were 1) an LTBI diagnosis 
recorded during the same 10-year period as cases, and 2) no documented history of previous 
TB disease. We patterned our choice of LTBI diagnosis as a basis for comparison with 
similar methods used to evaluate pulmonary impairment after TB.8 Whether a potential 
comparison subject has received LTBI treatment is not relevant to our intended adjustment 
for generalized non-TB risk factors such as lifestyle and socio-economic status, and was thus 
not considered in the eligibility criteria.
We used the CDC NDI to determine the vital status of persons in the two groups as of 31 
December 2008, allowing 6–16 years of retrospective observation for each subject. The NDI 
uses a probability algorithm to compare submitted data on full name, sex, birth date, and 
(when available) Social Security number with its death records 1) to classify persons with 
regard to vital status, and 2) to assess the strength and precision of the identifying 
information. Subjects classified by NDI with a probability score above the recommended 
cut-off threshold were defined as deceased, allowing a positive predictive value for mortality 
of >89%.21–23 The final results were de-identified for analysis.
Protocols for data collection and analysis were approved by the Texas Department of State 
Health (DHSH) Institutional Review Board (IRB), The University of North Texas Health 
Science Center Office for the Protection of Human Subjects (Fort Worth, TX, USA), and the 
CDC’s central IRB, as well as the respective IRBs of each participating site.
We calculated years of potential life lost (YPLL) for both groups. The YPLL represents the 
potential loss to death for each individual, and where the average difference of YPLL 
between the two cohorts is unequal, it indicates some disparity. YPLL were calculated using 
the life expectancy method.24 Where a subject had died, and YPLL were identified, we 
quantified that loss using the United States Life Tables, 2006.25 The YPLL therefore 
represents the individual’s difference between the observed age at death and the expected 
sex- and age-adjusted life expectancy, and this value was included as an additional data point 
for regression analysis. Because death was a relatively uncommon event during the 
observation period, a zero-inflated Poisson (ZIP) regression model was fitted to predict the 
expected YPLL in each cohort.26,27 The coefficients from the Poisson portion of the 
regression model (the expected YPLL) were used to predict the YPLL and absolute loss 
attributable to TB for population subgroups. The model controlled for known human 
immunodeficiency virus (HIV) status, TB history, age at treatment completion (for TB 
survivors) or entry into observation (for comparison subjects), time under observation, and 
demographic variables. If the HIV status was missing, it was assumed to be negative. The 
average predicted YPLLs were obtained for various subgroups. To test the effect of HIV and 
past TB disease on premature mortality, a separate ZIP regression analysis was modeled that 
excluded the 748 known HIV-positive cases and controls, and predicted YPLLs were 
compared between the HIV-inclusive group and the HIV-excluded group.
Summary YPLLs were calculated in a separate analysis to compare the loss of years in both 
cohorts and to help adjust for the relatively younger control group. YPLLs for 10-year age 
categories ranging from 18 to 85 years were calculated by subtracting the midpoint of each 
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age group from 85. The number of deaths in each age stratum was multiplied by the YPLL 
for that group and summed for each cohort.28 All analyses were performed using Stata 
Statistical Software Release 12 (StataCorp, College Station, TX, USA, 2011).
RESULTS
The final database included a cohort of 3933 cured TB patients and a comparable population 
of 9166 persons with LTBI. The demographic characteristics of case and control subject 
cohorts are shown in Table 1. Significant differences were present in the distribution of sex, 
race/ethnicity, age at entry into observation, geographic location, HIV status, foreign birth, 
and survival through the end of the observation period.
The LTBI comparison cohort was younger at enrollment (87.5% aged <50 years compared 
to 61.9% of the TB survivors, P < 0.001) and twice as often enrolled under the age of 30 
years. TB survivors were about nine times more frequently enrolled at age ≥70 years than 
LTBI comparison subjects. By the end of the 11-year observation period, 867 (22%) of the 
TB group and 364 (4%) of the LTBI group had died.
Expected life loss potentially attributable to TB
Sex-, race-, age-, HIV status- and nativity-controlled analysis predicted higher rates of 
longevity loss among study subjects with a history of fully treated TB relative to those with 
LTBI but no history of disease (incidence rate ratio 1.24, P < 0.001). Table 2 compares the 
predicted average YPLL for those who died during the observation period in the cured TB 
group and the LTBI control group. Cohort-wide, an adjusted average of 4.89 years are lost to 
those dying after completion of anti-tuberculosis treatment compared to a loss of 1.28 years 
from those dying after enrollment into the LTBI comparison group (P < 0.001). Subjects 
with both HIV infection and a history of TB were predicted to lose on average 16.3 potential 
life years (P < 0.001), and a sensitivity analysis exploring how robustly the full model 
controlled for the effects of HIV predicted less than half a year YPLL difference from the 
full model (data not shown). Among decedents, a history of fully treated TB is associated 
with an average 3.6 years of potential life loss relative to a comparable population with no 
history of active TB disease. Greater life loss is predicted for White and Hispanic TB 
survivors than for their Black and Asian counterparts, while immigrants were less likely to 
lose years of potential life compared to survivors born in the United States. Overall, a total 
of 14 035 YPLLs can be expected from the TB cohort (data not shown).
DISCUSSION AND IMPLICATIONS FOR POLICY AND PRACTICE
We found a greater-than-expected mortality burden in the years following anti-tuberculosis 
treatment completion relative to a similar population with no history of TB disease. On 
average, decedents with a history of fully treated TB lost an adjusted average of 4.89 
potential years of life relative to their sex-adjusted life expectancy. More significantly, most 
of this loss, 3.6 years, is associated with a history of active but fully treated TB. This TB-
attributable burden suggests another potential benefit associated with its prevention. In our 
study cohort of fewer than 4000 case subjects, these excess losses are substantial — a total 
of 14 158 life-years, or the equivalent of more than 188 75-year lifespans. Put another way, 
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these findings suggest that progress toward domestic elimination goals with a focus upon 
prevention comes with a tangible and important benefit beyond those commonly considered
—each incident case prevented may preserve an average of 3.6 potential years of life.
Our findings are consistent with those of others who found increased mortality in TB 
survivors compared to the national population.29,30 We used two different analytical models 
as well as alternative methods to evaluate the substantial difference in unadjusted death rate 
between cases and controls (22% and 4%, respectively). Our estimates remained robust, with 
consistent findings of a strong association between loss of potential life-years and TB 
survivorship, a potential loss similar to the more well-known attributable losses from 
tobacco use and obesity.31,32
This study has potential limitations, generally related to potential ascertainment and other 
biases that may arise from the use of administrative records as a data source. The original 
data set was collected retrospectively, and the maximum available duration of observation 
for any subject was ≤16 years. It is possible that premature mortality among TB survivors 
may continue beyond that period, which may lead to an underestimated mortality burden. It 
is feasible that the subjects captured in our data may not fully represent the populations we 
compared. In addition, both our analysis and the initial vital status determination were 
limited by missing data for risk and other variables related to individual study subjects. 
Missing data were not evenly distributed, and due to the nature of TB reporting and record 
keeping, we noted that data were more often missing from the control group. There are 
further limitations to the use of LTBI as a control group. Ascertainment bias could be 
present due to the circumstances leading to the report of past infection, such as incarceration 
or immigration. When LTBI status is determined, other risk factors, such as HIV status, may 
not be as diligently recorded compared to TB cases. It is likely true that TB is a marker for 
generally poor health and that some premature mortality identified in this population is due 
to predisposing factors for active TB, such as untreated comorbidities, drug or alcohol abuse 
or poor nutrition rather than sequelae of the disease itself. However, the chronic morbidities 
and the pulmonary and other impairments these impart are well understood, as are the 
population risks shared by those with LTBI and active TB.2–8 Given this, it seems likely that 
our premise and comparison methodologies are sufficient to plausibly explain a measurable 
association between a history of active TB and disproportionate premature death.
We found greater odds of survival among foreign-born subjects, and other studies have 
shown reduced mortality from active TB in immigrants.33,34 The differences seen in our 
study may support the ‘healthy immigrant’ hypothesis that relocation to another country is 
most likely to be practiced by healthier people, but our study did not capture deaths in study 
subjects who left the United States during or after the observation period, and we were 
unable to assess the time spent in the United States. Recent studies have noted that recent 
immigrants report a higher level of health than native-born persons, but the difference 
diminishes with increased tenure in the United States.35 Finally, although our data represent 
a diverse population from three distinct areas of the United States, findings drawn from 
analysis of only three geographic locations may not be fully generalizable to the US or other 
populations. We conducted analyses to identify the impacts of potential sampling bias and 
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data limitations as well as sensitivity to model selection, but found no evidence to 
fundamentally compromise our conclusions.
The difficulty in the elimination of remaining cases of TB in industrialised nations is that 
new cases and pockets of LTBI are clustered in hard-to-reach populations such as 
immigrants, the incarcerated, and the homeless. The political will to pursue an increasingly 
difficult and expensive goal of TB elimination is not certain, and evidence to shore up that 
political aim is vital. Our study suggests that even fully treated TB may not avert a 
substantial mortality burden, a compelling rationale for public investment and support for 
TB prevention.
Reducing the burden of TB in the United States and defining a path to elimination will 
require significant changes, not only to policy and practice, but also to the concept that 
treating LTBI is, from a societal standpoint, as important as treating active disease. Our 
understanding of how and when TB damages health continues to be challenged, and there is 
mounting evidence that the burden of TB does not end with the completion of adequate 
treatment. The association between potential life loss and past TB adds to that evidence and 
demonstrates that the burden is larger than realized. Further research may elucidate 
underlying risk factors for reduced longevity, and we recommend that long-term sequelae 
and death should be studied when assessing effectiveness of prevention.
Notwithstanding this somber news, we are also able to offer an additional conclusion that is 
much more optimistic: the means to achieving TB elimination through diligent prevention 
efforts are already available, are well accepted, and, given evidence such as that presented in 
this work, may be more valuable and efficient than currently understood.
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Table 1





n (%) P value*
Sex†
  Male 2453 (62.2) 4960 (56.0) <0.01
  Female 1480 (37.6) 3890 (44.0) <0.01
Race
  White 940 (23.9) 2890 (31.5) <0.01
  Black 981 (24.9) 1914 (20.9) <0.01
  Asian 1049 (26.7) 1757 (19.2) <0.01
  Hispanic 920 (23.4) 2519 (27.5) <0.01
  Other or unknown 43 (1.1) 86 (0.9) <0.01
Age at cohort entry, years‡
  18–30 788 (20.0) 3809 (41.6) <0.01
  30–50 1646 (41.9) 4210 (45.9) <0.01
  50–70 993 (25.2) 1019 (11.1) <0.01
  >70 506 (12.9) 128 (1.4) <0.01
Geographic location
  Massachusetts 1293 (32.9) 3320 (36.2) <0.01
  Seattle/King County 984 (25.0) 2515 (27.4)
  Texas 1656 (42.1) 3331 (36.3)
Known HIV-positive 350 (8.9) 398 (4.3) <0.01
Foreign-born† 2279 (57.9) 4964 (54.1) <0.01
*
χ2 test was used to compare binary or categorical variables.
†
Sex and foreign birth categories do not sum to n due to missing data.
‡
Student’s t-test was used to compare age at diagnosis.
TB = tuberculosis; LTBI = latent tuberculous infection; HIV = human immunodeficiency virus.
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Table 2





Absolute loss of years
attributable to TB
TB vs. LTBI 4.89 (4.27–5.51) 1.28 (1.10–1.47) 3.61
Sex
  Male 4.74 (4.13–5.34) 1.24 (1.06–1.42) 3.50
  Female 5.11 (4.46–5.77) 1.34 (1.14–1.54) 3.77
Race
  White 5.77 (4.77–6.78) 1.53 (1.25–1.82) 4.24
  Black 4.02 (3.26–4.78) 1.05 (0.83–1.27) 2.97
  Asian 4.27 (3.34–5.20) 1.11 (0.84–1.38) 3.16
  Hispanic 5.40 (4.44–6.35) 1.42 (1.14–1.69) 3.98
HIV-positive 16.33 (13.25–19.43) 4.64 (3.58–5.70) 11.69
Foreign-born 3.15 (2.63–3.67) 0.81 (0.67–0.95) 2.34
YPLL = years of potential life lost; TB = tuberculosis; CI = confidence interval; LTBI = latent tuberculous infection; HIV = human 
immunodeficiency virus.
Int J Tuberc Lung Dis. Author manuscript; available in PMC 2016 December 06.
